Your dog was diagnosed with Mast Cell Tumour — Low Grade. Most common skin tumour in dogs, accounting for ~17.8% of all canine cutaneous neoplasms. Kiupel low-grade represents approximately 85% of Patnaik Grade II tumours. Compare 6 treatment options for dogs including Wide Surgical Excision, Stelfonta (Tigilanol Tiglate), Palladia (Toceranib Phosphate) — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Mast Cell Tumour — Low Grade
Canine Oncology Treatment Guide
Mast Cell Tumour — Low Grade
Round Cell
About This Cancer
Mast cell tumours arise from mast cells, a type of immune cell found in connective tissues throughout the body that normally plays a role in allergic and inflammatory responses. These cells contain granules filled with histamine and other inflammatory chemicals, which can be released by the tumour, occasionally causing redness, swelling, or gastrointestinal upset. Mast cell tumours are the most common skin cancer in dogs and typically present as a lump in or under the skin. Low-grade tumours, as classified by the Kiupel grading system, generally behave in a relatively benign fashion — they grow slowly, are less likely to spread, and carry an excellent prognosis when completely removed surgically. Certain breeds, including Boxers, Pugs, Labrador Retrievers, and French Bulldogs, are predisposed. Even with a low-grade classification, complete surgical removal with adequate margins is important to prevent local recurrence.
Kiupel 2-Tier Histologic Grading System
Two-tier system (low-grade vs high-grade) replacing the older Patnaik 3-tier system. Reduces interobserver variability and provides clearer prognostic separation.
Prognostic Factors(5)
Minimum Workup(7 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.